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Abstract 
Introduction: Acute encephalopathy with biphasic seizures and late reduced diffusion (AESD) 
is the most common subtype of acute encephalopathy among children in Japan. The 
pathogenesis of AESD is mostly delayed cerebral edema caused by excitotoxic injury. It is 
difficult to discriminate AESD and complex febrile seizure in the early phase. Many cases have 
neurologic sequelae because early intervention is difficult. Methods: To establish an early 
diagnostic method, we assessed 213 hospitalized cases of febrile status epilepticus (FSE) 
between January 2004 and August 2014. We categorized FSE cases into an AESD group and a 
non-AESD group and compared their clinical courses, laboratory data and cranial computed 
tomography (CT) findings. Results: Of 213 hospitalized FSE cases, 19 (9%) were AESD. 
Univariate analysis showed that the AESD group took a significantly longer time to wake after 
FSE, had a higher degree of respiratory acidemia, and higher levels of serum AST, ALT, LD, 
hyperglycemia and hyperammonemia than the non-AESD group. We developed a scoring 
model that predicts AESD based on multivariate analysis. Using cut-off points of 4 and more 
with this scoring model, we could identify the AESD cases with 93% sensitivity and 91% 
specificity. These scores also had a positive correlation with prognosis. Discussion: Our scoring 
model enables early diagnosis of AESD. Patients with high scores should be observed carefully 
and early intervention should be considered.  
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1. Introduction 
Acute encephalopathy affects 400‒700 children per year in Japan, and AESD is the most 
common subtype of acute encephalopathy, accounting for about 30 % of all cases [1]. AESD 
has been reported as a new type of acute encephalopathy since the 1990s [2]. An overwhelming 
number of AESD cases occur in Japan, and most of the reports are from Japan. Typical AESD is 
characterized by FSE on the first day, followed by a transient recovery of consciousness. The 
secondary cluster of complex seizures occurs on days 3–6, with magnetic resonance imaging 
(MRI) showing a reduced diffusion in the subcortical white matter, or a “bright tree” appearance 
(BTA; Fig. 1). Affected children have various levels of neurological sequelae [3][4].  
It has been difficult to discriminate AESD and complex febrile seizure in the early phase, 
because both symptoms begin with FSE followed by a transient recovery of consciousness. And 
most cases have been treated after secondary seizures and under pathognomonic MRI findings. 
The pathogenic mechanism underlying AESD is mostly tied to excitotoxic injury. But an early 
diagnosis is still difficult, because no useful biomarker has been established. Furthermore, 
effective treatments have not been established, and many cases are not able to avoid 
neurological sequelae. 
In this report, we categorized FSE cases into an AESD group and non-AESD group and 
compared their clinical courses, laboratory data and cranial CT findings at the first medical 
examination to identify reliable clues for early diagnosis.  
2. Study design 
A retrospective research by a single institution.  
3. Patients 
We reviewed the cases of Japanese children younger than 16 years old with FSE who were 
treated in our institution from January 2004 to August 2014. We excluded children with acute 
encephalopathy other than AESD and acute encephalitis. We defined a febrile seizure as a 
seizure with fever (> 38. 0 °C), and FSE as a visible seizure lasting for > 30 minutes. Although 
some cases of AESD start with afebrile seizures, do not develop FSE or follow a biphasic 
course, we defined AESD based on the following criteria:  
 
1) Febrile seizure develops to FSE; 
2) Consciousness recovers during acute period except for children who have been continuously 
sedated; 
3) Secondary seizures or disturbance of consciousness appears 3‒6 days later; and 
4) Diffusion-weighted MR images show BTA at secondary phase.  
4. Methods 
We categorized FSE cases into an AESD group and a non-AESD group and compared their 
age (months) at onset, clinical course (seizure duration, time until waking, and number of drugs 
used), laboratory data and cranial CT findings. These data were accessed retrospectively using 
medical records. 
We selected a set of laboratory data that can be measured in any institution and has a short 
analysis time. Assuming that cases developing encephalopathy have severe seizure and a high 
degree of acidemia, and involve various organs, we used potential hydrogen (pH) levels, mixed 
venous partial pressure of CO2 (PvCO2) levels, serum lactic acid levels, serum aspartate 
transaminase (AST) levels, serum alanine transaminase (ALT) levels, serum lactate 
dehydrogenase (LD) levels, serum creatinine (Cr) levels, serum sodium levels, platelet count, 
blood glucose levels, and serum ammonia (NH3) levels. We recorded seizure duration every 5 
minutes and truncated any fraction less than 5 minutes.  
We recorded time until waking every 0. 5 hours from the last dose of anticonvulsive drugs and 
truncated any fraction less than 0. 5 hours.  
We defined waking as Glasgow coma scale (GCS) > 14. We recorded the laboratory data when 
the patients just arrived at the institution, so all data were during seizure or immediately after 
seizure.  
We performed the cranial CT immediately after the seizure had calmed down. We evaluated 
the neurodevelopmental outcome of AESD using the pediatric cerebral performance category 
(PCPC) scale [5] at 6‒12 months after the treatment, except for in cases that had underlying 
diseases affecting the score (Table 1).  
After visual inspection of variables, we employed the Mann-Whitney U nonparametric test to 
compare variables between the two groups, with the goal of developing a medical test for 
predicting AESD. Based on the results from univariate analyses described above, we chose a set 
of clinical variables that were associated with AESD. We employed a multivariable logistic 
regression model to evaluate the effects of risk factors simultaneously. In order to develop a 
clinically sound medical test, we constructed a scoring rule based on the estimates and their 
standard errors based on the results of univariate logistic models. Then, we conducted a 
receiver-operator characteristic (ROC) curve analysis to decide an optimal cut-off point.  
In addition, to investigate the availability of this predicting scoring model, we applied scores to 
other cases of encephalopathy and encephalitis that were excluded from the analysis.  
We conducted Spearman's rank correlation coefficient analyses on AESD patients and all 
encephalopathy and encephalitis patients to test for associations between PCPC scores and our 
novel AESD predicting scores.  
We performed all analysis using JMP Pro 11.2.1, and considered the probability value of < 
0.05 to indicate statistical significance.  
 
5. Results 
5.1. Patients 
During the study period, 223 cases met the criteria of FSE. Ten cases were excluded from 
analysis because of other acute encephalopathy or encephalitis. Of the 213 remaining cases were 
used for the analyses (Fig. 2). No patient repeated FSE in a single hospitalization period.  
Of the 213 patients, 122 (57%) were males, and the median age at onset was 23 months, 
ranging from 3 to 168 months. Sixty-six (31%) had a past history of febrile seizure. Fifty-three 
(25%) had neurologic diseases: epilepsy in 27 cases, mental retardation in 28, cerebral palsy in 
5, hydrocephalus in 4, Arnold-Chiari malformation in 2, cranioschisis in 1, hypoplasia of the 
corpus callosum in 3, low birth weight in 9, stroke in 1, encephalitis in 1, hypoxic ischemic 
encephalopathy in 4, congenital cytomegalovirus infection in 1, malformations of cortical 
development in 1, muscular dystrophy in 1, pervasive developmental disorder in 1, and 
chromosomal abnormality in 4, with some cases having more than one disease.  
In 12 patients (6%), visible seizure had already stopped when they arrived at the institution. 
In 107 (50%), seizures were stopped by a single drug: diazepam (DZP) in 103 cases, and 
midazolam (MDL) in 4. In 58 (27%), seizures were stopped by two drugs: DZP + MDL in 54 
and DZP + thiamylal in 4. For 35 patients (16%), seizures were stopped by three drugs: DZP + 
MDL + thiamylal in 34, and DZP + MDL + phenobarbital in 1. In 1 case, seizure was not 
stopped by three drugs.  
5.2. The features of AESD 
Of the 19 (9%) patients who were AESD (no repeated case), 8 (42%) were males.  Of the 4 
cases had neurologic diseases at the onset (hypoplasia of the corpus callosum and mental 
retardation in 1 case, mental retardation and epilepsy in 1, extremely low birth weight and 
mental retardation and epilepsy and stroke in 1, hypoplasia of the corpus callosum in 1).  
The median time of the secondary seizures from onset 5 days, ranging between 3 and 6 days. 
The consciousness from FSE to the secondary phase was clear in 4 cases, drowsy in 13 cases, 
and uncertain due to continuous sedation in 2 cases.  
The pathogens in cases of prodromal illness were Streptococcus pneumoniae meningitis in 1 
case, Haemophilus influenzae Type b (Hib) meningitis in 1, Hib bacteremia in 1, rotavirus 
gastroenteritis in 1, influenza A infection in 2, chickenpox in 2, human herpesvirus-6 infection 
in 1, respiratory syncytial virus infection in 1, upper respiratory infection due to unknown 
viruses in 4, acute pneumonia due to unknown viruses in 1, unknown in 4.  
Therapeutic hypothermia, which induced systemic cooling to 34 °C for 72 hours, was provided 
in 14 cases after secondary seizures. For 5 of these cases, steroid pulse therapy (methyl 
prednisolone 30 mg/ kg/ day for 3 days) and immunoglobulin therapy (1 g/ kg for single day) 
were simultaneously provided. For 2 of these cases, steroid pulse therapy was simultaneously 
provided. For 2 cases, steroid pulse therapy and immunoglobulin therapy were provided. For 2 
cases, specific therapies were not given.  
The neurologic sequelae were evaluated by PCPC score in 16 cases without underlying 
diseases that would affect the score. Seven cases were categorized as PCPC = 1, 3 cases were 
PCPC = 2, 5 cases were PCPC = 3, 1 case was PCPC = 4. In short, 56% of cases had neurologic 
sequelae. Incidentally, the non-AESD group had no neurologic sequelae.  
5.3. Comparison between AESD group and non-AESD group in clinical courses (Table 2） 
The age at onset was lower and the seizure duration was longer in the AESD group, but the 
differences were not statistically significant. The time until waking after FSE was significantly 
longer in the AESD group. The number of antiepileptic drugs to stop seizures was not 
significantly different among the two groups.  
5.4. Comparison between AESD group and non-AESD group in laboratory data（Table 3）  
The data were collected when we secured an intravenous catheter to administer the 
antiepileptic drugs. In the univariate analysis, the pH level was significantly lower and the 
PvCO2 level was higher in the AESD group. Level of blood glucose, AST, ALT, LD, Cr, and 
NH3 were also significantly higher in the AESD group. Other variables showed no significant 
difference between the two groups. There were no cases with underlying diseases such as 
kidney disease, liver disease, metabolic disease, or respiratory disease affecting these values.  
5.5.Cranial CT findings 
Cranial CT was performed on all 19 cases in the AESD group, and 188 cases in the non-AESD 
group. There were no abnormal changes found in either group at the early phase.  
5.6. Multivariate analysis 
We excluded PvCO2 from the predictors because pH and PvCO2 were strongly correlated 
with each other, and pH had a lower P value than PvCO2. We also excluded AST and LD but 
kept ALT as a predictor because they were strongly correlated with each other and AST and LD 
might be affected by hemolysis. Covariates for the multivariate logistic-regression analysis 
included time until waking after FSE, and levels of pH, blood glucose, ALT, Cr, and NH3. The 
multivariate analysis identified the time until waking after FSE, and levels of ALT, blood 
glucose, and NH₃ as significant independent predictors for AESD.  
5.7. Predicting scoring model for AESD 
Cutoff points using the area under the receiver-operating-characteristics (ROC) curve for each 
variable were as follows: time until waking after FSE ≥ 11 hours, pH < 7. 014, ALT ≥ 28IU/l, 
Cr ≥ 0. 3mg/dl, blood glucose ≥ 228mg/dl, NH3 ≥ 125μg/dl. Based on the estimates and their 
standard errors, we assigned 1 point for Cr ≥ 0. 3mg because it had the smallest effect among all 
predictors according to this analysis. We then assigned points to each predictor by comparing 
the ratio of estimates to its standard error with the equivalent ratio of Cr. We assigned 1 point 
for pH < 7. 014, Cr ≥ 0. 3mg/dl and 2 points for time until waking after FSE ≥ 11 hours, ALT ≥ 
28IU/l, blood glucose ≥ 228mg/dl, and NH3 ≥ 125 μg/dl (Table 4). We then derived the scores 
for 191 cases (AESD: 15 cases) that had no missing values for any predictor. Assuming that the 
score ≥ 4points was high risk, sensitivity and specificity were 93 % (14 / 15) and 91 % (160 / 
176) respectively, and the positive-predictive value was 47 % (14 / 30) (Fig. 3).  
When we also applied the scores to 8 cases of other acute encephalopathy and encephalitis 
with no missing values, which were excluded in the initial step, the sensitivity was 62 % (5 / 8).  
5.8. Correlation between scores and prognosis  
There was a positive correlation (Fig. 4) between our scoring model and the PCPC score in 
cases with no underlying diseases affecting the score (n = 13, rS = 0. 57). For all 
encephalopathy and encephalitis cases, our scoring model was also positively correlated with 
PCPC score (n = 21, rS = 0. 64).  
6. Discussion 
The pathogenesis of AESD has been suggested to be related to excitotoxic injury because 
AESD does not show hypercytokinemia, the IL-6 levels in the cerebrospinal fluid are elevated 
to protect the brain against the ischemic and excitotoxic damage, and the Glx 
(glutamate/glutamine complex) on proton MR spectroscopy (MRS) is elevated as an excitatory 
neurotransmitter [6][7][8]. Many cases of AESD have been reported in Japan. Genetic 
predispositions have also been reported and some relevant gene mutations and polymorphisms 
have been found [9][10]. The strength of excitement seems to be affected by these factors.  
In this study, the characteristics of cases developing AESD were 1) a longer time until waking 
after FSE, 2) higher degree of respiratory acidemia, and high levels of liver enzymes such as 
AST, ALT and LD, 3) a high Cr level, 4) hyperammonemia, and 5) hyperglycemia at the onset. 
These features might show that the excitement of seizures was stronger in the AESD group than 
in the non-AESD group.  
It is possible that the time until waking was affected by antiepileptic drugs, but there was no 
significant difference in the number of drugs used in the two groups. The consciousness 
disorders of AESD might be long because of the strong seizure itself and the secondary 
respiratory and cerebral circulation failure. A previous study reported that cases with a 
consciousness disorder lasting 12 hours after FSE were at high risk of acute encephalopathy 
[11]. The previous study also reported that some AESD patients and patients who took long 
time to wake after seizures were in a state of non-convulsive status epileptics (NCSE) 
[12][13][14].  
The acidemia might be caused by circulation failure, increase of the lactic acids due to 
cramps of the skeletal muscles, and respiratory depression. However, seizure duration was not 
simply related to the strength of the excitotoxin because it was not significantly different 
between the AESD and non-AESD groups. The lactic acids levels might be theoretically higher 
in AESD, but no significant difference between groups could be found, largely because of many 
missing values.  
High levels of AST, ALT, LD, NH3, and Cr could indicate liver and kidney damage due to 
respiratory and circulation failure. Several reports have examined the positive correlation 
between AST and prognosis in acute encephalopathy [15][16].  
Hyperglycemia would be caused by high levels of stress-related hormones such as 
catecholamine and cortisol. Several studies have reported that acidemia and hyperglycemia 
exacerbate the prognosis [15][17][18][19][20].  
Cranial CT was not a useful predictor because it did not show remarkable changes at the 
early phase.  
In this report, we could explore the clues of early diagnosis of AESD by a scoring model that 
we devised. The sensitivity and specificity of this scoring model were high, but the positive-
predictive value would depend on the incidence of AESD. Compared with the incidence of 
AESD in the previous reports, the positive-predictive value was 31.7%‒61.7 % 
[11][20][21][22].  
 Cases with high scores tended to have neurologic sequelae. In this report, many AESD cases 
experienced several levels of neurologic sequelae. Cases with high scores should be observed 
carefully by electroencephalogram to confirm whether they are in a state of NCSE.  
AESD has been treated with steroid pulse therapy and immunoglobulin therapy; however, 
these treatments would not be effective for AESD because hypercytokinemia is not the 
pathogenic mechanism as in other subtypes of acute encephalopathy [20]. On the other hand, 
early therapeutic hypothermia would be effective in preventing secondary energy failure after 
brain damage [23].  
Imataka reported that early introduction of therapeutic hypothermia immediately after FSE 
reduced the number of cases developing AESD [24]. Nakagawa et al. also reported that 
maintaining normothermia immediately after FSE reduced the prevalence of neurologic 
sequelae [25]. However, in childhood acute encephalopathy hypothermia is not effective if 12 
hour or more has passed after the brain damage [26]. Several studies have reported that an 
axonal damage marker, tau protein in cerebrospinal fluid and Glx on MRS, were already 
elevated on day 2‒3 [7][27]. But, because of the high invasiveness of therapy, it has been 
difficult to introduce it without obvious evidence of encephalopathy. AESD has been treated 
after secondary seizures and under pathognomonic MRI findings. However, at that point it may 
be too late to ameliorate brain damage. Therefore, early intervention is worth considering for 
cases with high risks, as identified by our scoring model.  
Our scoring model would also be useful in the early diagnosis of acute encephalopathy and 
encephalitis other than AESD with FSE. The pathogenesis of acute encephalopathy other than 
AESD would be hypercytokinemia, and damage to the brain and other organs would appear 
strongly in the early phase, as in the case of our study subjects.  
 
7. Limitations of this study 
First, because this study was conducted at a single institution, the number of AESD cases was 
limited. There is a possibility that the sensitivity, specificity and cut-off point of our scoring 
model would change with an increase in the sample size. Second, we investigated FSE patients 
only. However, some AESD cases do not start with FSE. Third, we did not consider NCSE 
because we included only visible seizures to calculate seizure duration. Fourth, we did not unify 
the interventional method. It is possible that the prognosis or incidence of AESD was affected 
by the interventions.  
We need to investigate cases in other institutions, increase the case number and verify the 
reproducibility of this study. Because there were significant differences between AESD and 
non-AESD cases in clinical course and laboratory data, we could establish an accurate scoring 
model with further analysis.  
8. Conclusions 
Our scoring model would enable early diagnosis of AESD. Cases with high scores should be 
observed carefully and early intervention should be considered.  
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Figure legends 
 
Fig. 1. Axial diffusion-weighted image shows high-intensity lesion in the subcortical white 
matter. AESD is characterized by this lesion.  
 
Fig. 2. We categorized the 223 cases of FSE into the AESD group and the non-AESD group and 
excluded 10 cases from analysis because of other acute encephalopathy or encephalitis.  
 
Fig. 3. Receiver-operator characteristic curve for the scoring model. For a cutoff of 4points, 
sensitivity and specificity were 93% and 91%, respectively. The area under the ROC curve of 
this scoring model was 0.96.  
 
Fig. 4. Correlation between score and prognosis. The score had positive correlation with PCPC 
score on AESD and all encephalopathy and encephalitis.  
 
 
 
 
 
 
 
 
 
 
 
Tables and legends 
Table 1  
Pediatric Cerebral Performance Category Scale.  
Clinical features Category Score 
・ normal for age 
・ school-age child attending regular school classroom 
normal 
 
1 
 
・ conscious, alert and able to interact at an age-appropriate level 
・ school-age child attending regular school classroom but grade 
perhaps not appropriate for age 
・ may have a mild neurologic deficit 
mild disability 
 
2 
・ conscious 
・ sufficient cerebral function for age-appropriate independent 
activities of daily life 
・ school-age child attending special education classroom 
・ may have learning deficit 
moderate disability 3 
・ conscious 
・ dependent on others for daily support because of impaired brain 
function 
severe disability 4 
・ any degree of coma without any of the criteria for brain death 
・ unawareness even if awake in appearance without interaction with 
the environment 
・ cerebral unresponsiveness 
・ no evidence of cortical function and not aroused by verbal stimuli 
・ possibly some reflexive responses, spontaneous eye opening and/or 
sleep-wake cycles 
coma or vegetative state 5 
・ apnea OR 
・ areflexia OR 
・ electroencephalographic (EEG) silence 
brain death 6 
 
 
 
 
 
Table 2  
Comparison between AESD and non-AESD in the clinical course.  
 AESD (n=19) non-AESD (n=194) P value 
clinical course median range Median range  
age at onset (months) 19 (7‒49) 23 (2‒168) 0.17 
seizure duration (minutes) 50 (30‒90) 40 (30‒100) 0.06 
time until waking (hours) 11.0 (7.0‒37.0) 4. 0 (0.5‒17.0) <0.01 
number of drugs used 2 (1‒3) 1 (0‒3) 0.55 
 
Table 3  
Comparison of laboratory data in AESD and non-AESD cases.  
 AESD non-AESD P value 
laboratory data median range n median range n  
pH 7.014 (6.746‒7.209) 17 7. 262 (6.778‒7.561) 187 <0.01 
PvCO2 88.8 (28.0‒226.0) 17 48. 5 (20.4‒182.8) 187 <0.01 
lactic acids (mg/dl) 38 (19‒66) 9 22 (6‒83) 102 0.87 
sodium (mEq/l) 137.3 (125.3‒147.9) 19 136. 0 (124.5‒167.0) 194 0.14 
AST (IU/l) 49 (24‒118) 19 36 (13‒112) 194 <0.01 
ALT (IU/l) 25 (7‒82) 19 15 (5‒57) 194 <0.01 
LD (IU/l) 329 (245‒410) 19 310 (119‒714) 194 0. 02 
Cr (mg/dl) 0. 34 (0. 26‒1. 07) 19 0. 27 (0. 07‒1. 47) 194 <0. 01 
platelet count (104/μl) 30. 4 (15. 6‒45. 0) 18 27. 1 (4. 3‒60. 2) 194 0. 16 
blood glucose (mg/dl) 244. 5 (14‒392) 18 159 (13‒381) 193 <0. 01 
ammonia (μg/dl) 126. 5 (23. 0‒307. 0) 18 72. 0 (14. 0‒286. 0) 190 <0. 01 
 
 
 
 
 
 
 
 
 
Table 4  
Multiple predictors of AESD in our scoring model.  
risk factor Estimate: a SE: b a/b (ratio between Cr) P value Score points 
pH<7. 014 -0. 975 0. 269 -3. 622 (1. 389) <0. 01 1 
ALT (IU/l) ≥28 -1. 264 0. 271 -4. 666 (1. 789) <0. 01 2 
blood glucose (mg/dl) ≥228 -1. 430 0. 284 -5. . 034 (1. 930) <0. 01 2 
time until waking (hours) ≥11. 0 -2. 084 0. 353 -5. 905 (2. 264) <0. 01 2 
Cr (mg/dl) ≥0. 3 -0. 672 0. 258 -2. 608 (1) <0. 01 1 
ammonia (μg/dl) ≥125 -1. 425 0. 230 -4. 756 (1. 824) <0. 01 2 
 
Fig. 1
Febrile status epilepticus: FS 
（n=223）
Acute encephalopathy with biphasic 
seizures and late reduced diffusion: 
AESD （n=19）
non-AESD （n=194）
Acute encephalopathy and encephalitis except AESD（n=10）
• Hemorrhagic shock and encephalopathy syndrome(HSES) (n=3)
• Unclassified encephalopathy (n=5)
• acute encephalitis (n=2)
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